Current management of hepatocellular carcinoma

Table 4 Result of randomized controlled trials: Adjuvant/neoadjuvant treatment in resected hepatocellular cancer

Ref.	Treatment	Recurrence rate-3 yr
Izumi et al[57] 1994	Adjuvant arterial lipiodolization (23) vs control (27)	No differences
Lai et al[58] 1998	Adjuvant chemoembolization (30) vs control (36)	82% vs 52%, P = NS
Yamasaki et al[59] 1996	Neoadjuvant chemoembolization (50) vs control (47)	54% vs 66%, P = NS
Lau et al[60] 1999	Adjuvant intraarterial lipiodol 131I (21) vs control (22)	75% vs 38%, P = 0.03
Lygidakis et al[61] 1996	Adjuvant chemoembolization + immunotherapy (49) vs control (42)	36 mo vs 18 mo (OS)
Takayama et al[62] 2000	Adjuvant immunotherapy (76) vs control (74)	33% vs 48%, P = 0.008
Yamamoto et al[63] 1996	Adjuvant 5-FU (35) vs control (32)	52% vs 75%, P = NS
Kubo et al[64] 2001	Adjuvant Interferon alpha (15) vs control (15)	30% vs 60%, P= 0.03

NS: Not significant; OS: Overall survival; FU: Fluorouracil.